Connect with us
News In Context
The Michael J. Fox Foundation understands that it can be challenging to gain clarity and perspective on breaking Parkinson's news. Q&As in this section are conducted with leading experts in the PD field to quickly provide an informed, impartial opinion on new findings — and get to the bottom of their implications for people with Parkinson's and for researchers.
Dr. Studer’s method shows new promise, reflecting the potential for dopamine cells’ survival and function in the brain.
The findings support a new emerging scientific understanding of alpha-synuclein, and could open up new approaches to develop treatments that target the protein.
Committee says that Teva Neuroscience did not provide sufficient evidence for Azilect to slow clinical progression in PD. Dr. Ken Marek, PPMI's principal investigator, explains what this recommendation could mean for people with Parkinson's.
10/06/2011 News in Context: Motor Improvement in Patients with DBS Sustained for up to 10 years
Dr. Andres Lozano comments on a new study's findings, and we hear from a patient who underwent the procedure 10 years ago, and another who is embarking on DBS.
Respondents focused their concerns on the placebo aspects of trial participation. Hear from an MJFF-funded researcher who is investigating the placebo effect in PD trials.
Jamie L. Eberling, PhD, associate director of research programs at The Michael J. Fox Foundation, comments on the findings.
On June 7, 2011 at the 15th International Congress of Parkinson's Disease and Movement Disorders (MDS) in Toronto, Canada, Abbott Laboratories revealed interim data from a long-term, open-label study treating advanced PD patients with levodopa-carbidopa intestinal gel (LCIG). MJFF spoke with Dr. Irene Richard and Dr. Hubert Fernandez to discuss what LCIG might meant for people with Parkinson's.
Pharmaceutical giant Eli Lilly and Company and Medtronic, Inc. announced a new Parkinson's drug-device collaboration to move the needle toward an effective GDNF-based treatment for PD. MJFF's Chief Program Officer Todd Sherer, PhD, explains what this initiative could mean to the treating of symptoms and possibly even the progression of Parkinson's.
04/12/2011 News in Context: UMD Study Reports Benefits of Exercise for PD Patients
According to an MJFF-funded study at the University of Maryland School of Medicine, low-intensity exercise improves walking in PD patients. The Michael J. Fox Foundation spoke with Bastiaan Bloem, MD, a researcher on the MJFF-funded ParkFit Study, to learn more about exercise therapy for people with Parkinson's.
03/22/2011 News in Context: Gene Therapy Trial Reports Improvements in PD Symptoms
On March 16, The Lancet Neurology published results from a randomized, controlled, double-blind phase II clinical trial of a novel gene therapy (NLX-P101) for Parkinson's Research. The Michael J. Fox Foundation spoke with Irene Hegeman Richard, MD, Associate Professor of Neurology and Psychiatry at the University of Rochester School of Medicine and an author of the paper, to learn more about what the study results may mean for people with PD.
Connect with us